Drugs / BI-1607
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06784648 | Dec 2024 → Dec 2025 overdue | cutaneous melanoma, metastatic melanoma, uveal melanoma | BioInvent International AB | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05555251 | Jul 2022 → Feb 2024 | HER2 positive breast carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | BioInvent International AB | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI-1607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05555251 ↗ |
| Action | Inhibit | “BI-1607 is a human mAb that specifically blocks FcγRIIB” PMID 41071338 ↗ Dec 2025 |
| Modality | Monoclonal antibody | “BI-1607 is a human mAb” PMID 41071338 ↗ Dec 2025 |
| Route | Intravenous | “administered at different doses in Phase I by intravenous infusions every 3 weeks.” NCT05555251 ↗ |